We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+212.2%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$456M
AUM Growth
+$209M
Cap. Flow
+$8.86M
Cap. Flow %
1.94%
Top 10 Hldgs %
77.4%
Holding
26
New
2
Increased
8
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$19.7M
2
DYN icon
Dyne Therapeutics
DYN
+$13.9M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$12.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$11.2M
5
ABVX
Abivax
ABVX
+$11M

Top Sells

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$28.5M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$13.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$7.31M
4
ASND icon
Ascendis Pharma A/S
ASND
+$6.59M
5
ARGX icon
argenx
ARGX
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11.2B
$68M 14.92%
801,224
+178,745
+29% +$11M
AMLX icon
2
Amylyx Pharmaceuticals
AMLX
$2.17B
$62.6M 13.72%
4,604,878
+1,344,308
+41% +$12.7M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$16B
$39.6M 8.69%
300,610
+93,658
+45% +$11.2M
DYN icon
4
Dyne Therapeutics
DYN
$4.24B
$33.8M 7.42%
2,674,469
+1,219,040
+84% +$13.9M
COGT icon
5
Cogent Biosciences
COGT
$6.91B
$29.1M 6.38%
2,025,041
-272,483
-12% -$3.23M
PCVX icon
6
Vaxcyte
PCVX
$8.01B
$28.4M 6.23%
788,441
+244,220
+45% +$8.09M
CELC icon
7
Celcuity
CELC
$4.01B
$23.4M 5.13%
473,828
-711,692
-60% -$28.5M
CGON icon
8
CG Oncology
CGON
$6.48B
$23.4M 5.12%
579,895
-6,752
-1% -$196K
IRON icon
9
Disc Medicine
IRON
$2.85B
$22.5M 4.94%
340,897
-55,218
-14% -$3.28M
PHVS icon
10
Pharvaris
PHVS
$2.37B
$22.1M 4.85%
+886,332
New +$19.7M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.36B
$20.2M 4.44%
503,701
+35,337
+8% +$1.24M
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$17.8M 3.91%
734,539
-58,788
-7% -$1.04M
MRUS
13
DELISTED
Merus
MRUS
$17.3M 3.8%
184,135
-40,125
-18% -$2.61M
LENZ
14
LENZ Therapeutics
LENZ
$179M
$17.1M 3.76%
368,176
+25,864
+8% +$951K
OCUL icon
15
Ocular Therapeutix
OCUL
$1.89B
$13.5M 2.95%
1,151,686
+423,110
+58% +$5.06M
MNPR icon
16
Monopar Therapeutics
MNPR
$739M
$12.7M 2.78%
+155,370
New +$6.95M
NAMS icon
17
NewAmsterdam Pharma
NAMS
$3.53B
$4.36M 0.96%
153,147
-67,548
-31% -$1.62M
ARGX icon
18
argenx
ARGX
$55.6B
– –
-10,285
Closed -$5.67M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.6B
– –
-38,191
Closed -$6.59M
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
– –
-62,793
Closed -$710K
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$1.66B
– –
-290,784
Closed -$13.7M
NBIX icon
22
Neurocrine Biosciences
NBIX
$17.7B
– –
-58,181
Closed -$7.31M
REPL icon
23
Replimune Group
REPL
$724M
– –
-128,917
Closed -$1.2M
SLN
24
Silence Therapeutics
SLN
$570M
– –
-34,737
Closed -$201K
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-500,551
Closed -$4.69M
1
2

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Saturn V Capital Management held 26 positions worth $456M, up 85% from $247M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Saturn V Capital Management's Q3 2025 filing shows 2 new, 8 increased, 7 reduced and 9 closed positions. Its largest new stake was Pharvaris: 886,332 shares worth $22.1M. The largest sale was Celcuity, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Saturn V Capital Management's largest Q3 2025 buy was Pharvaris: 886,332 shares worth $22.1M.
  • Saturn V Capital Management added most to Dyne Therapeutics in Q3 2025, an estimated $13.9M increase.
  • Saturn V Capital Management's biggest Q3 2025 reduction was Celcuity, cutting an estimated $28.5M.
  • Saturn V Capital Management fully exited MoonLake Immunotherapeutics in Q3 2025, selling an estimated $13.7M.
  • Saturn V Capital Management's ten largest holdings make up 77% of its $456M portfolio in Q3 2025.
  • Saturn V Capital Management opened 2 new positions and closed 9 in Q3 2025.
  • Saturn V Capital Management's portfolio value rose 85% quarter-over-quarter to $456M.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.